Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Open Access
- 10 January 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 104 (2), 93-113
- https://doi.org/10.1093/jnci/djr511
Abstract
With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall survival has improved, and patients are being treated continuously for increasingly long periods of time. This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab (in combination with interferon alpha), temsirolimus, and everolimus. Suggestions for monitoring and managing AEs have been published, but there are few consensus recommendations. In addition, there is a risk that patients will be subjected to multiple unnecessary investigations. In this review, we aimed to identify the level of supporting evidence for suggested AE management strategies to provide practical guidance on essential monitoring and management that should be undertaken when using targeted agents. Five databases were systematically searched for relevant English language articles (including American Society of Clinical Oncology abstracts) published between January 2007 and March 2011; European Society of Medical Oncology congress abstracts were hand searched. Strategies for AE management were summarized and categorized according to the level of recommendation. A total of 107 articles were identified that describe a large number of different investigations for monitoring AEs and interventions for AE management. We identify and summarize clear recommendations for the management of dermatologic, gastrointestinal, thyroid, cardiovascular, and other AEs, based predominantly on expert opinion. However, because the evidence for the suggested management strategies is largely anecdotal, there is a need for further systematic investigation of management strategies for AEs related to targeted therapies for RCC.Keywords
This publication has 97 references indexed in Scilit:
- Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGETEuropean Journal of Cancer, 2010
- Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the managementAnnals of Oncology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialThe Lancet Oncology, 2009
- Could Rigorous Diagnosis and Management of Hypertension Reduce Cardiac Events in Patients With Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors?Journal of Clinical Oncology, 2009
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancerCancer, 2009
- Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapyNature Reviews Clinical Oncology, 2009
- Search for Evidence-Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)The Oncologist, 2009
- Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2008
- Heart failure associated with sunitinib malateCancer, 2008